Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals is expected to benefit from increasing volumes in the ACTH gel market, particularly through its products Cortrophin Gel and Acthar Gel, with projected growth continuing into 2025. Financial projections indicate that the company’s adjusted operating margin is anticipated to rise from 25.4% in 2024 to 29.7% by 2028, alongside the generation of over $630 million in operating cash flow during the years 2025-2028. Additionally, upcoming launches and increasing prescription volumes for products like Promethazine Hydrochloride and Dextromethorphan Oral Solution, alongside Prucalopride, are expected to drive revenue growth, leading to revised revenue estimates for FY 2025 upwards to $269.5 million.

Bears say

ANI Pharmaceuticals Inc has reported a significant decline in revenue for its Brands segment during the second and third quarters of 2024, driven by unfavorable market conditions for specific products, notably Cortrophin, which has experienced ongoing pricing pressures. These issues are compounded by anticipated seasonal declines exceeding 30% in the first quarter of 2025 due to Medicare-related challenges and reduced patient access to funding from non-profit organizations. Although the company has exceeded revenue and EBITDA expectations for recent quarters, persistent margin pressures and the evolving market landscape contribute to a fundamentally negative outlook for the stock.

ANI Pharma (ANIP) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 13 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.